Status:

ACTIVE_NOT_RECRUITING

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Lead Sponsor:

AbbVie

Conditions:

Ulcerative Colitis (UC)

Eligibility:

All Genders

18-99 years

Brief Summary

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Eligibility Criteria

Inclusion

  • For enrollment into the HUMIRA treatment group; adult patients with moderately to severely active UC who has been prescribed HUMIRA therapy according to routine clinical practice and meets one of the following:
  • Is currently taking HUMIRA therapy and has received at least 8 weeks of therapy; OR
  • Is entering after participation in an Abbott or AbbVie sponsored UC study and; has received continuous HUMIRA therapy since initiation of therapy
  • For enrollment into the IMM treatment group; adult patients with moderately to severely active UC who has been prescribed IMM therapy, is currently taking IMM therapy, and has received at least 12 consecutive weeks of IMM therapy
  • Patients capable of and willing to grant authorization for use/disclosure of data being collected and provided to AbbVie prior to any registry-related data being collected, and to comply with the requirements of the Registry protocol

Exclusion

  • Patients on IMM therapy without a concurrent biologic if they cannot continue to be treated with IMM therapy or
  • Patients who are being treated with any investigational agents and/or approved biologics other than Humira.

Key Trial Info

Start Date :

April 29 2013

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2028

Estimated Enrollment :

8250 Patients enrolled

Trial Details

Trial ID

NCT01848561

Start Date

April 29 2013

End Date

June 1 2028

Last Update

July 16 2025

Active Locations (512)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 128 (512 locations)

1

Birmingham Gastroenterology Associates P.C /ID# 102063

Birmingham, Alabama, United States, 35209

2

University of Alabama at Birmingham - Main /ID# 131646

Birmingham, Alabama, United States, 35233

3

Longwood Research /ID# 118662

Huntsville, Alabama, United States, 35801

4

East View Medical Research, LLC /ID# 116259

Mobile, Alabama, United States, 36606

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | DecenTrialz